BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:07 PM
 | 
Oct 22, 2012
 |  BC Extra  |  Company News

FDA denies immediate Contrave review but open to 'faster' path

Orexigen Therapeutics Inc. (NASDAQ:OREX) said FDA denied the company's request to immediately review and issue a decision on an NDA for Contrave instead of waiting for data from the agency-required cardiovascular study of the obesity product. However, Orexigen said that FDA is open to the possibility of...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >